Frequently asked questions: HRT

Practitioner

Volumn 249, Issue 1676, 2005, Pages 778-782

  Mansour, Diana ^a  

^a Department of Community Gynaecology and Reproductive Health Care ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28144444724     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Committee on Safety of Medicines. Hormone Replacement Therapy (HRT): Latest Safety Update. London: CSM, 3 December 2003 http://tinyurl.com/cqz33
2. Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side-effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-988
3. Porter M, Penney GC, Russell D et al. A population-based survey of women's experience of the menopause. Br J Obstet Gynaecol 1996;103:1025-1028
4. Oldenhave A, Jaszmann LJ, Haspels AA et al. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780
5. Rioux JE, Devlin C, Gelfand MM et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161
6. Dezarnaulds G, Fraser IS. Vaginal ring delivery of hormone replacement therapy - a review. Expert Opin Pharmacother 2002;4:201-212
7. Weisberg E, Ayton R, Darling G et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-93
8. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultra-low doses of 17beta-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944-947
9. Dugal R, Hesla K, Sordal T et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-297
10. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52
11. Ballagh SA. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med 2005;23:126-140
12. Bagger YZ, Tanko LB, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-735
13. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
14. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
15. British National Formulary. London: British Medical Association, September 2005 http://tinyurl.com/al654
16. Crosbie D, Reid DM. Managing osteoporosis. The Practitioner 2004;248;749-751
17. Gupta S. Progestogen-only contraception: a review. The Practitioner 2005;249:90-102
18. Keen R. Casebook: osteoporosis. The Practitioner 2005;249:639-643